IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

/PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell...

Related Keywords

Shanghai ,China ,Peking ,Beijing ,United States ,Nanjing ,Jiangsu ,Tongji ,Sichuan ,Huazhong ,Hubei ,Chinese ,American ,Chunrui Li ,Jue Wang ,Innovent Biologics ,Equecabtagene Autoleucel ,Adimab Incyte ,Eli Lilly ,Innovent Biologics Inc ,Union Medical College ,China National Medical Products Administration ,Huazhong University Of Science Technology ,American Society Of Hematology ,Md Anderson Cancer Center ,Tongji Medical College ,Chinese Academy Of Medical Sciences ,Institute Of Hematology ,American Society ,Efficacy Outcomes ,Multiple Myeloma ,San Diego ,Associate Professor ,Tongji Hospital ,Huazhong University ,Professor Lu Gui Qiu ,Blood Diseases Hospital ,Chinese Academy ,Medical Sciences ,Peking Union Medical College ,New Drug Application ,National Medical Products Administration ,Sintilimab Injection ,Bevacizumab Injection ,Adalimumab Injection ,Rituximab Injection ,Pemigatinib Oral Inhibitor ,Ramucirumab Injection ,Selpercatinib Capsules ,Autoleucel Injection ,Tafolecimab Injection ,Cancer Center ,